Precision BioSciences, Inc
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform. The company develops in vivo therapies for genetic and infectious diseases and also licenses ARCUS-related intellectual property to collaborators and other biotechnology companies.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of proprietary genome editing tools and therapeutic candidates for human disease.
Upfront payments, milestones, and royalties from partners using ARCUS-related IP.
Asiakkaat
Precision BioSciences sells primarily to pharmaceutical and biotechnology partners through licensing and collaboration agreements, while its internal programs are aimed at future patients with genetic or infectious diseases. Its commercial counterparties are research-driven companies that need access to genome-editing IP, preclinical know-how, or therapeutic development rights. If approved, future products would be used by hospitals, specialists, and treatment centers rather than sold directly to consumers.
License ARCUS IP or partner on preclinical programs in exchange for upfront fees, milestones, and royalties.
Patients with genetic or infectious diseases who would receive approved ARCUS-based therapies.
Companies and institutions that use ARCUS in discovery, preclinical, or translational work.
Strategia
The company’s strategy is to advance ARCUS-based in vivo therapies while using partnerships and licensing to monetize its platform before full product commercialization. It also seeks to expand its intellectual property portfolio and manufacturing know-how so it can support future clinical and commercial development. These priorities are intended to preserve optionality across both internal drug development and external licensing.
Internal programs are the main path to long-term value creation and future product revenue.
Partner deals can generate non-product revenue and external validation of ARCUS technology.
Genome editing is highly IP-intensive and requires strong preclinical and manufacturing execution.
Maantiede
Precision BioSciences is headquartered in the United States and conducts its research, development, and corporate activities from there. Its collaboration and licensing model can reach global partners, but the company’s operating footprint is centered on U.S.-based scientific and regulatory infrastructure. Because its programs are pre-commercial, geography matters mainly through where trials, partners, and regulatory approvals are pursued.
Riskit
Precision BioSciences faces the typical risks of a clinical-stage gene editing company: uncertain clinical outcomes, regulatory approval risk, and heavy dependence on intellectual property protection. Its business also depends on third-party collaborators, contract research and manufacturing providers, and future access to capital, which can all affect timing and execution. As a pre-commercial company, it is also exposed to cybersecurity, patent, and biosimilar competition risks if any products are approved.
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
Therapeutic candidates are still in development and may not show safety or efficacy.
Kohdistuu: In vivo gene editing programs
- Financing riskVaikutus: KorkeaTodennäköisyys: Korkea
The company has not generated product sales and relies on external capital to fund R&D.
Kohdistuu - Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Gene editing products face stringent FDA and foreign review, with possible restrictions or denial.
Kohdistuu: Future BLA or foreign marketing applications
- Intellectual property and license riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The business depends on patents and license agreements that can expire or be challenged.
Kohdistuu: ARCUS platform and Cellectis-related license terms
- Partner concentration and collaboration riskVaikutus: KeskitasoTodennäköisyys: Korkea
A meaningful part of revenue comes from collaboration accounting and partner milestones.
Kohdistuu - Cybersecurity and third-party execution riskVaikutus: KeskitasoTodennäköisyys: Matala
R&D, manufacturing, and collaborator data flows depend on external systems and vendors.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätRevenue depends on performance obligations, deferred revenue release, and milestone events.
Vaikutus: Can cause large fluctuations unrelated to current-period cash receipts
Prior upfront payments are recognized over time or at contract completion.
Vaikutus: Major driver of year-to-year revenue variability
A meaningful non-cash expense for a small, research-intensive biotech company.
Vaikutus: Affects operating loss and comparability across periods
The company uses leased facilities and third-party research/manufacturing services.
Vaikutus: Affects balance sheet liabilities and operating expense timing
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
Praxis Precision Medicines, Inc.
PRAX · Pharmaceutical Preparations
Precigen, Inc
PGEN · Pharmaceutical Preparations
Editas Medicine, Inc.
EDIT · Biological Products, (No Diagnostic Substances)
Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms.
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026